Incyte Corporation (INCY) Shares Bought by Temasek Holdings Private Ltd
Temasek Holdings Private Ltd lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 25.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 252,160 shares of the biopharmaceutical company’s stock after acquiring an additional 50,856 shares during the period. Temasek Holdings Private Ltd owned 0.12% of Incyte worth $29,437,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Oppenheimer Asset Management Inc. raised its position in shares of Incyte by 9.9% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 27,147 shares of the biopharmaceutical company’s stock worth $3,418,000 after acquiring an additional 2,455 shares in the last quarter. Pinebridge Investments L.P. raised its position in shares of Incyte by 122.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 74,590 shares of the biopharmaceutical company’s stock worth $9,392,000 after acquiring an additional 40,992 shares in the last quarter. Calamos Advisors LLC increased its position in Incyte by 37.7% during the second quarter. Calamos Advisors LLC now owns 113,132 shares of the biopharmaceutical company’s stock worth $14,244,000 after buying an additional 30,990 shares during the period. Inverness Counsel LLC NY acquired a new position in Incyte during the third quarter worth approximately $330,000. Finally, Tredje AP fonden increased its position in Incyte by 63.4% during the second quarter. Tredje AP fonden now owns 22,446 shares of the biopharmaceutical company’s stock worth $2,826,000 after buying an additional 8,706 shares during the period. 90.86% of the stock is currently owned by institutional investors and hedge funds.
Incyte Corporation (INCY) opened at $93.71 on Wednesday. Incyte Corporation has a 12 month low of $93.49 and a 12 month high of $153.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82.
Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The company had revenue of $381.50 million for the quarter, compared to the consensus estimate of $360.34 million. During the same period last year, the business posted $0.19 EPS. The company’s revenue was up 41.6% on a year-over-year basis. research analysts anticipate that Incyte Corporation will post -1.33 EPS for the current year.
In other Incyte news, EVP Reid M. Huber sold 696 shares of Incyte stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $98.01, for a total value of $68,214.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Barry P. Flannelly sold 714 shares of Incyte stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $124.25, for a total value of $88,714.50. Following the completion of the transaction, the executive vice president now owns 15,496 shares in the company, valued at $1,925,378. The disclosure for this sale can be found here. Insiders sold a total of 104,334 shares of company stock worth $11,992,011 over the last quarter. Company insiders own 17.70% of the company’s stock.
Several research firms have commented on INCY. ValuEngine lowered Incyte from a “hold” rating to a “sell” rating in a research report on Wednesday, November 29th. Evercore ISI began coverage on Incyte in a research report on Wednesday, August 16th. They set an “in-line” rating and a $135.00 price target on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $163.00 price target (down previously from $172.00) on shares of Incyte in a research report on Monday, September 11th. Goldman Sachs Group began coverage on Incyte in a research report on Friday, October 6th. They set a “buy” rating and a $160.00 price target on the stock. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Incyte in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Incyte currently has an average rating of “Buy” and a consensus price target of $145.65.
ILLEGAL ACTIVITY NOTICE: “Incyte Corporation (INCY) Shares Bought by Temasek Holdings Private Ltd” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/12/06/incyte-corporation-incy-shares-bought-by-temasek-holdings-private-ltd.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.